Wall Street analyst estimates for Fortrea Holdings Inc. (FTRE): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development.
Consensus price target
$23.07 (+15 % vs price $20.02)
between $16.00 and $29.00 · 6 targets published in the last quarter
Closing price, Nov 2
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2027E | $2.8B | $2.7B – $2.8B | $1.06 | 7 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 5 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (−2 sell to +2 buy) | 0.46 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-25 | $0.20 | ||
| 2026-10-29 | $0.28 | $0.22 | +28.9% |
| 2026-07-29 | $0.23 | $0.18 | +27.5% |
| 2026-05-05 | $0.16 | $0.03 | +433.3% |
| 2026-02-26 | $0.09 | $0.16 | -43.8% |
| 2025-11-05 | $0.12 | $0.16 | -25.0% |
| 2025-08-06 | $0.19 | $0.06 | +216.7% |
| 2025-05-12 | $0.02 | $-0.07 | +128.6% |
Valuation Ratios
| Price / Book | 3.60 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.58B | $3.06B | $2.84B | $2.84B | $2.70B | $2.72B |
| Cost of Revenue | $2.09B | $2.45B | $2.11B | $2.25B | $2.16B | $2.30B |
| Gross Profit | $489.1M | $604.4M | $724.4M | $590.6M | $534.2M | $425.8M |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | $267.6M | $303.1M | $416.1M | $448.1M | $560.7M | $456.4M |
| Operating Expenses | $803.3M | $490.1M | $537.3M | $558.6M | $696.1M | $456.4M |
| Operating Income | -$314.2M | $114.3M | $187.1M | $32.0M | -$161.9M | -$30.6M |
| EBITDA | $221.5M | $302.9M | $280.8M | $137.2M | -$64.3M | -$813.6M |
| Interest Expense | 0 | $200,000 | $200,000 | $69.8M | $123.8M | $91.4M |
| Pre-tax Income | -$332.2M | $136.4M | $187.0M | -$30.5M | -$275.0M | -$983.0M |
| Income Tax | $27.0M | $38.4M | $41.1M | $1.2M | -$3.5M | $3.2M |
| Net Income | -$359.2M | $98.0M | $186.2M | -$25.2M | -$328.5M | -$986.2M |
| EPS | -$4.06 | $1.11 | $2.11 | -$0.04 | -$3.67 | -$10.81 |
| EPS (Diluted) | -$4.06 | $1.11 | $2.11 | -$0.04 | -$3.67 | -$10.81 |
| Shares Outstanding (Diluted) | 88.4 M | 88.4 M | 88.4 M | 88.8 M | 89.5 M | 91.2 M |
Price
| Price | $20.02 (closing price, November 2, 2026) |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: XNCR · MRVI · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of FTRE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks